Analysis of the Relationship Between Primary Tumor Site and Clinicopathological Characteristics and Survival Prognosis of Breast Cancer Patients Based on SEER Database
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.08.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Yumeng Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: SEER Program, Nomograms, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Xi'an Jiaotong University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: This study aimed to analyze the association between the primary tumor site and clinicopathological characteristics and survival prognosis of breast cancer (BC) patients using a large population database. METHODS: BC patients screened in the Surveillance, Epidemiology, and End Results (SEER) database were categorized into 6 groups based on primary sites. Descriptive statistics, Kaplan-Meier curves, Cox regression models, forest plots were used to assess the effect of primary sites on overall survival (OS) and breast cancer-specific survival (BCSS). Multivariate Cox proportional analyses were conducted to calculate hazard ratios (HRs) and adjusted subgroups' hazard ratios (AHRs). Nomograms were utilized to predict OS and BCSS. RESULTS: Among 193,043 BC patients, the highest incidence was found in the upper outer quadrant (52.60%). Central portion patients are associated with more clinical features indicating a poor prognosis, and had worse OS and BCSS than other sites. Univariate and multifactorial Cox analyses showed associations between OS/BCSS and various factors. Subgroup analyses revealed differences in OS and BCSS between central portion and upper outer quadrant varied among age, T and N stage. The nomogram was established to predict the survival of central portion BC patients. CONCLUSIONS: Primary tumor site is associated with clinicopathological features and prognosis of BC, may be influenced by age at diagnosis and T and N stage. Central portion BC patients have worse prognosis due to older age at diagnosis, higher T stage and higher likelihood of lymph node metastasis. Early diagnosis and treatment may help to improve survival of central portion BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- School of Basic Medical Sciences, Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education, Xi'an Jiaotong University, Xi'an, China.
- The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: kanghuafeng1973@126.com.
Förderung
- Xi'an Jiaotong University
Zitieren
APA
Wei, Y., Liu, P., Liu, X., Wang, M., Liu, D., Cui, H., Lin, S., Wu, H., Ma, X., & Kang, H. (2024). Analysis of the Relationship Between Primary Tumor Site and Clinicopathological Characteristics and Survival Prognosis of Breast Cancer Patients Based on SEER Database. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.08.021
Vancouver
Wei Y, Liu P, Liu X, Wang M, Liu D, Cui H, et al. Analysis of the Relationship Between Primary Tumor Site and Clinicopathological Characteristics and Survival Prognosis of Breast Cancer Patients Based on SEER Database. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.08.021
BibTeX
@article{Wei2024,
author = {Wei, Yumeng and Liu, Peinan and Liu, Xingyu and Wang, Meng and Liu, Dandan and Cui, Hanxiao and Lin, Shuai and Wu, Hao and Ma, Xiaobin and Kang, Huafeng},
title = {Analysis of the Relationship Between Primary Tumor Site and Clinicopathological Characteristics and Survival Prognosis of Breast Cancer Patients Based on SEER Database},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.08.021}
}
EUVIMED